zongertinib · Boehringer Ingelheim · NDA 219042
Hernexeos
Earliest generic entry, as listed
21 Jul 2041
Blocked by patent: US 11608343.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11608343 | drug substance, drug product, use U-4245 · sets the listed date | 21 Jul 2041 |
| US 12171739 | drug substance, drug product | 15 Nov 2026 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 8 Aug 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219042 · 001 · RLD | tablet, oral | 60MG | 21 Jul 2041 |